ロード中...
EO9 (Apaziquone): from the clinic to the laboratory and back again
EO9 (Apaziquone) is a bioreductive drug that has a chequered history. It underwent clinical trial but failed to show activity in phase II clinical trials when administered i.v. Poor drug delivery to tumours caused by a combination of rapid pharmacokinetic elimination and poor penetration through ava...
保存先:
| 主要な著者: | , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Blackwell Publishing Ltd
2013
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3569998/ https://ncbi.nlm.nih.gov/pubmed/22509926 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1476-5381.2012.01996.x |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|